OncoMatch/Clinical Trials/NCT02974647
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Is NCT02974647 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ruxolitinib for lymphoma.
Treatment: Ruxolitinib — The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Excluded: JAK2 fusion
T-cell Lymphoproliferative diseases with JAK2 fusion [excluded]
Disease stage
Required: Stage IB OR GREATER (FOR CTCL) (Lugano Classification (systemic lymphoma); mSWAT (CTCL))
For CTCL, patients with stage IB disease or greater are eligible. Measurable disease defined by: Lugano Classification for systemic lymphoma or Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood or bone marrow or mSWAT > 0 or Sezary count ≥ 1000 cells/μL for CTCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic anti-cancer therapy
Relapse or refractory disease after at least 1 systemic therapy except for T-PLL, LGL, or T-cell Lymphoproliferative diseases with JAK2 fusion
Cannot have received: JAK inhibitor (ruxolitinib)
Prior therapy with ruxolitinib
Lab requirements
Blood counts
ANC ≥ 1.0/mm^3 or ≥ 0.5/mm^3 if baseline neutropenia due to lymphoma; platelets ≥ 100 x 10^9/L or ≥ 50 x 10^9/L if related to lymphoma; Hgb ≥ 8g/dL; LGL or T-PLL not required to meet minimum ANC or hemoglobin
Kidney function
Creatinine clearance ≥ 30 mL/min; creatinine clearance of 15-29 mL/min allowed if baseline platelets ≥ 150 x 10^9/L
Liver function
Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN if documented hepatic involvement with lymphoma, or ≤ 5 x ULN if history of Gilbert's; AST and ALT ≤ 3 x ULN; ≤ 5 x ULN if due to lymphoma involvement
Patients must meet the following lab criteria: ANC ≥ 1.0/mm^3 or ≥ 0.5/mm^3 (if patient has baseline neutropenia due to lymphoma), platelets ≥ 100 x 10^9/L or ≥ 50 x 10^9/L (if related to lymphoma), Hgb ≥ 8g/dL; LGL or T-PLL not required to meet a minimum ANC or hemoglobin value for eligibility; Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN if documented hepatic involvement with lymphoma, or ≤ 5 x ULN if history of Gilbert's; AST and ALT ≤ 3 x ULN; ≤ 5 x ULN if due to lymphoma involvement; Creatinine clearance ≥ 30 mL/min; creatinine clearance of 15-29 mL/min will be allowed as long as baseline platelets are ≥ 150 x 10^9/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
- Northwestern Medicine (Data collection and specimen analysis) · Chicago, Illinois
- Dana Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify